Keyphrases
Graft-versus-host Disease (GvHD)
100%
High Dose
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Non-Hodgkin Lymphoma
100%
Cyclophosphamide
100%
Etoposide
100%
Carmustine
100%
Previous Chemotherapy
33%
Chemotherapy Regimen
33%
Total Body Irradiation
33%
Non-relapse Mortality
33%
Aggressive non-Hodgkin Lymphoma
33%
High Risk
16%
Confidence Interval
16%
Liver Disease
16%
Overall Survival
16%
Leukoencephalopathy
16%
Hematopoietic Cell Transplantation
16%
Allogeneic
16%
Follow-up Time
16%
Cyclosporine
16%
Conditioning Regimen
16%
Autologous Transplantation
16%
Recurrent Disease
16%
Event-free Survival
16%
Venous Disease
16%
Methylprednisolone
16%
Preparative Regimen
16%
HLA-matched Donor
16%
Diffuse Alveolar Hemorrhage
16%
Event Probability
16%
Medicine and Dentistry
Hematopoietic Stem Cell
100%
Cell Transplantation
100%
Drug Megadose
100%
Non-Hodgkin Lymphoma
100%
Cyclophosphamide
100%
Etoposide
100%
Carmustine
100%
Graft Versus Host Reaction
33%
Patient History of Chemotherapy
33%
Whole Body Radiation
33%
Chronic Graft Versus Host Disease
33%
Acute Graft Versus Host Disease
33%
Chemotherapy Regimens
33%
Infection
16%
Overall Survival
16%
Leukoencephalopathy
16%
Event Free Survival
16%
Recurrent Disease
16%
Cyclosporine
16%
Conditioning
16%
Autotransplantation
16%
Methylprednisolone
16%
Vein Occlusion
16%
Pulmonary Hemorrhage
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Etoposide
100%
Cyclophosphamide
100%
Carmustine
100%
Acute Graft Versus Host Disease
50%
Chronic Graft Versus Host Disease
50%
Graft Versus Host Reaction
50%
Patient History of Chemotherapy
50%
Chemotherapy Regimens
50%
Infection
25%
Overall Survival
25%
Recurrent Disease
25%
Ciclosporin
25%
Event Free Survival
25%
Methylprednisolone
25%
Vein Occlusion
25%
Leukoencephalopathy
25%
Lung Hemorrhage
25%
Immunology and Microbiology
Hematopoietic Cell
100%
Drug Megadose
100%
Cell Transplantation
100%
Cyclophosphamide
100%
Chronic Graft Versus Host Disease
33%
Graft-Versus-Host Disease
33%
Acute Graft Versus Host Disease
33%
Overall Survival
16%
Conditioning
16%
Ciclosporin
16%
Autotransplantation
16%
Methylprednisolone
16%
Event Free Survival
16%